The first large randomized trial of statins in healthy adults over 70 finally has results, and they point in two directions at once. Atorvastatin cut major cardiovascular events by 30 percent. It did not help anyone live longer, avoid dementia or stay out of a wheelchair. Both of those findings came out of the same 9,971 people, which is why the coverage has been all over the place since the results landed.
What the Trial Actually Tested
STAREE enrolled 9,971 adults from Australian general practice, mean age 74.7, about 52 percent women. Everyone in it was free of cardiovascular disease, diabetes and dementia at the start, which is the whole point. This was not a study of people who had already had a heart attack. It was a study of healthy older people being asked whether to start a pill they may not need. That question affects an enormous number of Americans. Primary prevention in the over 70 group has been one of the biggest evidence gaps in cardiology, and doctors have been making the call on extrapolation from younger trials.
Atorvastatin 40 Milligrams Against Placebo
Participants were randomized one to one to atorvastatin 40 milligrams daily or a placebo, and followed for a median of 5.9 years. The results were presented at the European Society of Cardiology Congress in Munich on August 30 and published the same day in the New England Journal of Medicine. The lead investigator was Sophia Zoungas of Monash University in Melbourne, and the trial recruited through Australian general practices rather than hospital cardiology clinics, which is closer to how the decision actually gets made.
The Cardiovascular Result Was Clear
Major cardiovascular events occurred in 6.0 percent of the atorvastatin group and 8.3 percent of the placebo group, a hazard ratio of 0.70. In raw numbers that is 297 events against 412. The composite counted cardiovascular death, nonfatal heart attack, stroke and coronary revascularization. A 30 percent relative reduction in that group of outcomes is a real effect and not a marginal one. The absolute difference was 2.3 percentage points over almost six years, which is the number worth holding onto. Relative reductions always sound larger than the thing they describe.
The Survival Result Was Not
The trial’s other main endpoint was disability free survival, meaning staying alive without dementia or persistent physical disability. There 12.8 percent of the atorvastatin group and 13.6 percent of the placebo group had an event, which is not a statistically meaningful difference. The investigators wrote that the lower incidence of major nonfatal cardiovascular events did not result in a corresponding improvement in disability free survival. In raw counts that was 637 events against 676, close enough that the trial cannot claim a difference.
Why Those Two Findings Can Coexist
The benefit was concentrated in nonfatal events. Fewer heart attacks and strokes that people survive is genuinely good, and it is not the same thing as fewer deaths or less disability. In a population averaging almost 75, other causes of death and decline compete hard enough that preventing some cardiac events does not necessarily move the overall survival curve within six years. It is also possible the benefit shows up later. Six years is a long trial and a short window in the life of somebody who starts a medication at 75.
Side Effects Were Mostly Reassuring
Serious adverse events came in at 2.7 percent in both arms, which is as clean a safety signal as this kind of trial produces. Muscle and musculoskeletal complaints, liver related events and diabetes related events were all more common in the atorvastatin group. Those are the known statin issues and they showed up on schedule. None of them appeared at a rate that would make a cardiologist flinch, but they are the reasons patients stop taking statins in the real world, where nobody is checking in every three months.
The Coverage Split Three Ways
Different outlets read the same data differently. Some led with the 30 percent reduction. Some led with the null result on disability free survival. Some led with the caveat that the benefit was driven mainly by nonfatal events. All three framings are accurate, which is a good sign that the trial produced a genuinely mixed result rather than a clean one. If you only read one headline about this study you almost certainly got a version of it that was true and incomplete.
What It Means for a Guideline
Nothing has changed yet. Primary prevention statin recommendations for people over 70 have always been softer than for younger adults, precisely because the evidence was thin. Now the evidence exists and it says the pill prevents heart attacks and strokes without extending healthy life over six years. Cardiology societies will have to decide what to do with that, and no one has announced a change. Anyone already on a statin for existing heart disease is in a completely different category and this trial says nothing about them.
Frequently Asked Questions
What is the STAREE trial?
A randomized trial of atorvastatin 40 milligrams versus placebo in 9,971 healthy Australian adults over 70, presented at the European Society of Cardiology Congress on August 30, 2026.
Did statins reduce heart attacks and strokes?
Yes. Major cardiovascular events occurred in 6.0 percent of the statin group versus 8.3 percent on placebo, a 30 percent relative reduction.
Did statins help people live longer?
No. Disability free survival was 12.8 percent versus 13.6 percent, which was not a significant difference.
How long were participants followed?
A median of 5.9 years.
Were there side effects?
Serious adverse events were 2.7 percent in both groups, but muscle, liver and diabetes related events were more common with atorvastatin.
Should older adults stop taking statins because of this?
No one should change medication based on a single trial. This study looked only at people with no existing cardiovascular disease, and any decision belongs with a doctor who knows the individual case.
